Abstract: A method for adjudicating reimbursement for allergens includes obtaining National Drug Codes (NDC's) for a plurality of allergens, storing in a central control database the obtained NDC's in association with an associated AWP and associated information for the allergen, which associated information includes translation information to allow practitioners to determine from a desired diluted level and number of doses of a desired NDC carrying antigen and a known dilution procedure how to translate back to the amount of base concentration of the NDC carrying antigen used to create the desired diluted level and number of doses, and determining if any of the NDC's in the central control database are contained within the third-party database and, if not, transferring the associated NDC's not in the third-party database to the third-party database.

Abstract: A method for adjudicating reimbursement for allergens includes obtaining National Drug Codes (NDC's) for a plurality of allergens, storing in a central control database the obtained NDC's in association with an associated AWP and associated information for the allergen, which associated information includes translation information to allow practitioners to determine from a desired diluted level and number of doses of a desired NDC carrying antigen and a known dilution procedure how to translate back to the amount of base concentration of the NDC carrying antigen used to create the desired diluted level and number of doses, and determining if any of the NDC's in the central control database are contained within the third-party database and, if not, transferring the associated NDC's not in the third-party database to the third-party database.

Abstract: An apparatus for performing chemosensory disorder testing includes an application for installation on a mobile computing device. The application includes a set of instructions to receive a scanning signal from a scanner communicating with the mobile computing device, the scanning signal including a unique identifier. The application next identifies a predetermined scent responsive to the scanning signal. The application generates multiple choice display for display on a display screen associated with the mobile computing device, the multiple-choice display includes an indication associated with the identified predetermined scent and at least one indication associated with another scent. The application receives a test response input from the display screen responsive to an input from a test subject attempting to detect the predetermined scent.

Abstract: A therapeutic treatment kit includes a container for holding a plurality of compartmentalized therapeutic dispensers. Each of the therapeutic dispensers includes a plurality of vials of antigens, and a plurality of containers of supplements disposed in compartments, each of the compartments labeled with the name of the supplement. A compartment is also provided for containing applicators or the antigens, such that an individual can extract the antigen from the vial in a single dose; and para instructions associated with a therapeutic program for utilizing the vials of antigens and the supplements in accordance with a therapeutic program that is predefined. The construction of the kit, including the dosages of the antigen, the types of antigens and the supplements all associated with a particular therapeutic program.

Abstract: A method for creating a consolidated compound for delivering an immunomodulatory and imiquimod to a patient, comprising diluting immunomodulator extract to a desired dilution by transferring a desired quantity of the concentrated immunomodulator to an associated sterile container, the associated sterile container having a defined volume of diluted immunomodulator after dilution thereof, providing a viscous encapsulation material, selecting a prescribed amount of concentrated immunomodulator, the prescribed amount defined as that amount of the diluted immunomodulator extract required to provide a number of doses equal to the number of dispensable increments from the container containing the viscous encapsulation material, introducing the selected amount of each of the diluted immunomodulator extract into the viscous encapsulation material, introducing an amount of imiquimod into the viscous encapsulation material, and mixing the introduced amount of each of the diluted immunomodulator extracts and the introduc

Abstract: A method for delivering an immunomodulator to a patient includes providing a bottle of concentrated immunomodulator extract; progressively diluting the antigen extract in sterile bottles; selecting a prescribed amount from a desired one of the dilution bottles; providing a viscous encapsulation material that is able to introduce antigens contained therein through the skin of a patient; introducing one or more doses of the selected prescribed amount of diluted immunomodulator into the viscous encapsulation material; disposing a prescribed amount of viscous encapsulation material containing the introduced diluted immunomodulator therein within a container that is able to dispense such viscous encapsulation material containing the introduced diluted immunomodulator; dispensing from the container the amount of viscous encapsulation material containing the diluted immunomodulator in an amount equal to a single dose; and applying the dispensed viscous encapsulation material containing the introduced diluted immunom

Abstract: A method for delivering allergens to a pharmacist in a pre-diluted kit form, comprising providing a bulk container of base concentrate antigen containing at least one antigen at a predetermined concentrated level, creating a sequential and more diluted sequence of antigens, providing a plurality of end-use sealable containers that can receive a finite end amount of diluted antigens, dispensing from each of sequential bulk containers a finite end amount of diluted antigens into one of the plurality of end-use sealable containers, wherein the end-use seal containers filled from each of the sequential bulk containers comprises a group of end-use sealable containers associated with each of the sequential bulk containers, sealing each of the end-use containers after diluted antigens are disposed therein, and disposing a select number of the sealed end-use sealable containers from each of the groups of end-use sealable containers into a container comprising a kit.

Abstract: A method for creating a consolidated compound for delivering an immunomodulatory and imiquimod to a patient, comprising diluting immunomodulator extract to a desired dilution by transferring a desired quantity of the concentrated immunomodulator to an associated sterile container, the associated sterile container having a defined volume of diluted immunomodulator after dilution thereof, providing a viscous encapsulation material, selecting a prescribed amount of concentrated immunomodulator, the prescribed amount defined as that amount of the diluted immunomodulator extract required to provide a number of doses equal to the number of dispensable increments from the container containing the viscous encapsulation material, introducing the selected amount of each of the diluted immunomodulator extract into the viscous encapsulation material, introducing an amount of imiquimod into the viscous encapsulation material, and mixing the introduced amount of each of the diluted immunomodulator extracts and the introduc

Abstract: A therapeutic treatment kit includes a container for holding a plurality of compartmentalized therapeutic dispensers. Each of the therapeutic dispensers includes a plurality of vials of antigens, and a plurality of containers of supplements disposed in compartments, each of the compartments labeled with the name of the supplement. A compartment is also provided for containing applicators or the antigens, such that an individual can extract the antigen from the vial in a single dose; and para instructions associated with a therapeutic program for utilizing the vials of antigens and the supplements in accordance with a therapeutic program that is predefined. The construction of the kit, including the dosages of the antigen, the types of antigens and the supplements all associated with a particular therapeutic program.

Abstract: An apparatus for performing chemosensory disorder testing includes an application for installation on a mobile computing device. The application includes a set of instructions to receive a scanning signal from a scanner communicating with the mobile computing device, the scanning signal including a unique identifier. The application next identifies a predetermined scent responsive to the scanning signal. The application generates multiple choice display for display on a display screen associated with the mobile computing device, the multiple-choice display includes an indication associated with the identified predetermined scent and at least one indication associated with another scent. The application receives a test response input from the display screen responsive to an input from a test subject attempting to detect the predetermined scent.

Abstract: A method for administering tests using a regional antigen testing kit is provided. The method comprises providing the regional antigen testing kit, extracting a predetermined amount of concentrated antigen from one of a plurality of concentrated antigens, dispensing the predetermined amount of concentrated antigen into a corresponding one of a plurality of wells, as indicated by visual indicia, repeating the extracting and dispensing steps until a desired number of the plurality of wells contain concentrated antigen, providing a prick tester having a plurality of needles extending thereon, aligning the plurality of needles of the prick tester with the plurality of wells, inserting each of the plurality of needles of the prick tester into one of the plurality of wells, and applying the plurality of needles of the prick tester to the skin of a patient to elicit a potential response.

Abstract: A system for chemosensory disorder testing includes a scanner for scanning a unique identifier associated with a test subject. A scent dispensing unit dispenses a predetermined scent for the test subject responsive to receipt of a dispensing control signal. A user interface receives a test response input from the test subject based on a perception of the test subject of the predetermined scent dispensed by the scent dispensing unit. A central controller generates the dispensing control signal responsive to the unique identifier scanned by the scanner. The central controller further determines at least one of a pass test result or a fail test result responsive to a comparison of the test response input to a predetermined response associated with the predetermined scent. A relational database stores the pass test result or the fail test result at a location associated with the unique identifier associated with the test subject.

Abstract: A method for adjudicating reimbursement for allergens includes obtaining National Drug Codes (NDC's) for a plurality of allergens, storing in a central control database the obtained NDC's in association with an associated AWP and associated information for the allergen, which associated information includes translation information to allow practitioners to determine from a desired diluted level and number of doses of a desired NDC carrying antigen and a known dilution procedure how to translate back to the amount of base concentration of the NDC carrying antigen used to create the desired diluted level and number of doses, and determining if any of the NDC's in the central control database are contained within the third-party database and, if not, transferring the associated NDC's not in the third-party database to the third-party database.

Abstract: An access system has a scanner that scans a unique identifier to access a location. A display receives an input. An automated dispenser dispenses at least one scent on each hand of an individual responsive to a control signal. A processor controls access to the location. A memory stores a set of instructions that configures the processor to receive the unique identifier from the scanner, actuate the automated dispenser to dispense the at least one scent responsive to receipt of the unique identifier, receive the response input based on the scents detected by the individual of the at least one scent, determine a passing result or a failing result responsive to the received response input and an expected response based on the dispensed at least one scent, enable access to the location responsive to a passing result and deny access to the controlled access location responsive to a failing result.

Abstract: A method for creating a multi-antigen patch, comprising providing one or more transdermal patch sheets having a plurality of single dose transdermal patches residing thereon, wherein each one of the plurality of single dose transdermal patches includes an antigen at a particular dilution level disposed within a carrier, removing one or more of the plurality of single dose transdermal patches from the one or more transdermal patch sheets, adhering the one or more of the plurality of single dose transdermal patches to a backing, wherein the backing allows for multiple single dose transdermal patches to be adjacently adhered thereon, and covering the plurality of transdermal patches adhered to the backing with a peelable release liner.

Abstract: A method for delivering allergens to a pharmacist in a pre-diluted kit form, comprising providing a bulk container of base concentrate antigen containing at least one antigen at a predetermined concentrated level, creating a sequential and more diluted sequence of antigens, providing a plurality of end-use sealable containers that can receive a finite end amount of diluted antigens, dispensing from each of sequential bulk containers a finite end amount of diluted antigens into one of the plurality of end-use sealable containers, wherein the end-use seal containers filled from each of the sequential bulk containers comprises a group of end-use sealable containers associated with each of the sequential bulk containers, sealing each of the end-use containers after diluted antigens are disposed therein, and disposing a select number of the sealed end-use sealable containers from each of the groups of end-use sealable containers into a container comprising a kit.

Abstract: A method for adjudicating reimbursement for venom derived allergens between a pharmacist and a reimbursing entity comprises obtaining National Drug Codes (NDC's) for a plurality of venom derived allergens, storing in a central control database the obtained NDC's in association with an associated AWP and associated information for the venom derived allergen, which associated information includes translation information to allow practitioners to determine from a desired diluted level and number of doses of a desired NDC carrying venom derived antigen and a known dilution procedure how to translate back to the amount of base concentration of the NDC carrying venom derived antigen used to create the desired diluted level and number of doses, and determining if any of the NDC's in the central control database are contained within the third-party database and, if not, transferring the associated NDC's not in the third-party database to the third-party database.

Abstract: A method for delivering allergens to a pharmacist in a pre-diluted kit form, comprising providing a bulk container of base concentrate antigen containing at least one antigen at a predetermined concentrated level, creating a sequential and more diluted sequence of antigens, providing a plurality of end-use sealable containers that can receive a finite end amount of diluted antigens, dispensing from each of sequential bulk containers a finite end amount of diluted antigens into one of the plurality of end-use sealable containers, wherein the end-use seal containers filled from each of the sequential bulk containers comprises a group of end-use sealable containers associated with each of the sequential bulk containers, sealing each of the end-use containers after diluted antigens are disposed therein, and disposing a select number of the sealed end-use sealable containers from each of the groups of end-use sealable containers into a container comprising a kit.

Abstract: A prick test kit comprises a bottom tray containing a plurality of wells disposed in an array, wherein each of the wells contains a vial of a small amount of a specific well associated antigen, with each well and associated vial having a different antigen disposed therein, each of the vials having a rubber cap disposed thereon that is sterile and able to be pricked by a needle such that the small amount of antigen can be removed therefrom. A penetrating plate is disposed above the wells and having on the lower surface thereof diametrically opposite from the vials in the wells a plurality of piercing needles, one associated with each of the wells and directed downward there to but not touching any of the files. A separating plate is disposed between the bottom tray and the penetrating plate. A sterile covering is provided for containing the entire assembly.

Abstract: A method for producing prick test single use sterile vials for use in a prick test is provided. The method comprises providing at least one allergen source including therewithin allergen extract, providing a plurality of single dose vials, connecting a tube to the at least one allergen source, connecting a metering device to the tube, drawing by the tube an amount of the allergen extract from one of the at least one allergen source, receiving the amount of allergen extract at the metering device, and dispensing by the metering device a volume of allergen extract into one of the plurality of single dose vials.